JP5954918B2 - 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法 - Google Patents

未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法 Download PDF

Info

Publication number
JP5954918B2
JP5954918B2 JP2008544561A JP2008544561A JP5954918B2 JP 5954918 B2 JP5954918 B2 JP 5954918B2 JP 2008544561 A JP2008544561 A JP 2008544561A JP 2008544561 A JP2008544561 A JP 2008544561A JP 5954918 B2 JP5954918 B2 JP 5954918B2
Authority
JP
Japan
Prior art keywords
cell
tumor
cells
dendritic cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008544561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518045A5 (OSRAM
JP2009518045A (ja
Inventor
オールトン エル． ボイントン，
オールトン エル． ボイントン，
マーニックス エル． ボッシュ，
マーニックス エル． ボッシュ，
Original Assignee
ノースウエスト バイオセラピューティクス， インコーポレイテッド
ノースウエスト バイオセラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースウエスト バイオセラピューティクス， インコーポレイテッド, ノースウエスト バイオセラピューティクス， インコーポレイテッド filed Critical ノースウエスト バイオセラピューティクス， インコーポレイテッド
Publication of JP2009518045A publication Critical patent/JP2009518045A/ja
Publication of JP2009518045A5 publication Critical patent/JP2009518045A5/ja
Application granted granted Critical
Publication of JP5954918B2 publication Critical patent/JP5954918B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2008544561A 2005-12-08 2006-12-08 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法 Active JP5954918B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74888505P 2005-12-08 2005-12-08
US60/748,885 2005-12-08
PCT/US2006/047083 WO2007067782A2 (en) 2005-12-08 2006-12-08 Compositions and methods for inducing the activation of immature monocytic dendritic cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013162033A Division JP2013223517A (ja) 2005-12-08 2013-08-05 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2016035257A Division JP2016105725A (ja) 2005-12-08 2016-02-26 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2009518045A JP2009518045A (ja) 2009-05-07
JP2009518045A5 JP2009518045A5 (OSRAM) 2012-11-29
JP5954918B2 true JP5954918B2 (ja) 2016-07-20

Family

ID=38123555

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2008544561A Active JP5954918B2 (ja) 2005-12-08 2006-12-08 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2013162033A Pending JP2013223517A (ja) 2005-12-08 2013-08-05 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2016035257A Withdrawn JP2016105725A (ja) 2005-12-08 2016-02-26 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2017122256A Withdrawn JP2017158595A (ja) 2005-12-08 2017-06-22 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2018238996A Withdrawn JP2019062904A (ja) 2005-12-08 2018-12-21 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2021000066A Withdrawn JP2021045176A (ja) 2005-12-08 2021-01-04 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2023175234A Pending JP2023171524A (ja) 2005-12-08 2023-10-10 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2013162033A Pending JP2013223517A (ja) 2005-12-08 2013-08-05 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2016035257A Withdrawn JP2016105725A (ja) 2005-12-08 2016-02-26 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2017122256A Withdrawn JP2017158595A (ja) 2005-12-08 2017-06-22 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2018238996A Withdrawn JP2019062904A (ja) 2005-12-08 2018-12-21 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2021000066A Withdrawn JP2021045176A (ja) 2005-12-08 2021-01-04 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2023175234A Pending JP2023171524A (ja) 2005-12-08 2023-10-10 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法

Country Status (14)

Country Link
US (2) US20080254537A1 (OSRAM)
EP (3) EP3072958A1 (OSRAM)
JP (7) JP5954918B2 (OSRAM)
KR (6) KR20220113543A (OSRAM)
CN (2) CN101336291A (OSRAM)
AR (1) AR056851A1 (OSRAM)
AU (1) AU2006321794A1 (OSRAM)
BR (1) BRPI0619499A2 (OSRAM)
CA (1) CA2632263C (OSRAM)
CR (1) CR10048A (OSRAM)
IL (2) IL191930A (OSRAM)
RU (1) RU2008122550A (OSRAM)
TW (1) TW200800252A (OSRAM)
WO (1) WO2007067782A2 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2464228C (en) 2000-10-27 2017-01-17 Immuno-Rx, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
JP5647601B2 (ja) * 2008-04-14 2015-01-07 アイ アール エックス セーラピューティクス， インコーポレイテッド Ｉｒｘ−２の改良された作製方法
US8728806B2 (en) * 2008-12-06 2014-05-20 The Board Of Regents, The University Of Texas System Methods and compositions related to Th-1 dendritic cells
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
ES2711504T3 (es) * 2009-07-24 2019-05-06 Rhode Island Hospital Vacunas de células dendríticas para tumores que expresan asparaginil-beta-hidroxilasa
EP2470906A4 (en) * 2009-08-24 2013-10-02 Univ Columbia ASSAY FOR DETERMINING THE HEALTH OF CD8 + T-CELLS
AU2010307075B2 (en) 2009-10-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
US9333238B2 (en) 2009-12-08 2016-05-10 Irx Therapeutics, Inc. Method of immunotherapy for treament of human papillomavirus infection
WO2012065156A2 (en) * 2010-11-13 2012-05-18 University Of Florida Research Foundation, Inc. Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
NL2009102C2 (en) * 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
TWI503414B (zh) * 2012-07-05 2015-10-11 Fullhope Biomedical Co Ltd 一種製備專一性ｔ細胞之配方、方法及其配方製備方法
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
WO2014093454A1 (en) 2012-12-12 2014-06-19 Orbis Health Solutions, Llc Compositions and methods for tissue regeneration
ES2548229T3 (es) * 2012-12-18 2015-10-15 Immunicum Ab Co-diferenciación de monocitos procedentes de donantes alogénicos
CN104936612B (zh) * 2013-09-05 2021-01-01 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
CN103756960A (zh) * 2013-12-04 2014-04-30 深圳市合一康生物科技有限公司 一种高毒性、高增值能力的人d-cik细胞的专用试剂盒
CN103784950A (zh) * 2014-01-22 2014-05-14 北京弘润源生物技术有限公司 乳腺癌特异抗原表位多肽负载的树突状细胞疫苗制备及其试剂盒
CN106456532B (zh) 2014-03-05 2020-07-24 奥比思健康解决方案有限责任公司 使用酵母细胞壁颗粒的疫苗递送系统
CN103800897B (zh) * 2014-03-12 2017-03-22 李金珍 一种肿瘤特异抗原表位多肽负载的树突状细胞疫苗制备方法及其试剂盒
JP6434139B2 (ja) * 2014-06-23 2018-12-05 ジェイダブリュ クレアジェン インコーポレイテッド 特定遺伝子発現が増加した樹状細胞の製造方法およびこれを利用して製造された樹状細胞を含む自己免疫疾患治療または予防用組成物
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
EP3350318B1 (en) * 2015-09-15 2022-04-13 NorthWest Biotherapeutics, Inc. Methods relating to activated dendritic cell compositions for subjects with advanced cancers
CN105647867A (zh) * 2016-02-28 2016-06-08 深圳爱生再生医学科技有限公司 诱导树突状细胞成熟的方法和树突状细胞
CN105670994A (zh) * 2016-02-28 2016-06-15 深圳爱生再生医学科技有限公司 Dc诱导剂及其应用
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN109844100A (zh) * 2016-09-01 2019-06-04 株式会社理研免疫再生医学 制备天然杀伤t(nkt)细胞刺激性树突细胞的方法及制备含有nkt细胞刺激性树突细胞和nkt细胞的细胞组合物的方法
WO2018061006A1 (en) * 2016-09-29 2018-04-05 Hadasit Medical Research Services And Development Ltd. Dendritic cell preparations, compositions thereof and methods of using same
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
JP6881331B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP6881333B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP6881332B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
KR20210042142A (ko) * 2018-08-10 2021-04-16 주식회사 유틸렉스 암항원 특이적 cd8+ t 세포의 제조 및 동결보존 방법
CN110106145B (zh) * 2019-06-12 2021-02-12 蓝莲(杭州)生物科技有限公司 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法
CN116056716B (zh) * 2020-05-15 2025-10-31 首尔大学校产学协力团 利用从脂肪组织分离出来的基质血管组分的树突状细胞的激活功能的免疫反应增强用组合物
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
WO1998046083A1 (en) * 1997-04-17 1998-10-22 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
WO2003010292A2 (en) 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
EP2322603B1 (en) * 2001-09-06 2019-10-16 NorthWest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response
AU2003243673B2 (en) 2002-06-19 2010-01-21 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for leukocyte enrichment
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
ES2321939T3 (es) * 2003-02-27 2009-06-15 Northwest Biotherapeutics, Inc. Generacion de celulas dendriticas a partir de celulas precursoras dendriticas monociticas con gm-csf en ausencia de citoquinas adicionales.

Also Published As

Publication number Publication date
WO2007067782A2 (en) 2007-06-14
KR20080109717A (ko) 2008-12-17
JP2019062904A (ja) 2019-04-25
IL229348B (en) 2018-12-31
TW200800252A (en) 2008-01-01
CN101336291A (zh) 2008-12-31
KR20220113543A (ko) 2022-08-12
CN103589684A (zh) 2014-02-19
JP2021045176A (ja) 2021-03-25
CA2632263C (en) 2022-01-11
US20080254537A1 (en) 2008-10-16
WO2007067782A3 (en) 2008-02-14
JP2013223517A (ja) 2013-10-31
KR20180049169A (ko) 2018-05-10
KR20210013327A (ko) 2021-02-03
CA2632263A1 (en) 2007-06-14
AU2006321794A1 (en) 2007-06-14
EP1957634A2 (en) 2008-08-20
JP2009518045A (ja) 2009-05-07
US20120244620A1 (en) 2012-09-27
CR10048A (es) 2008-09-17
JP2016105725A (ja) 2016-06-16
JP2017158595A (ja) 2017-09-14
AR056851A1 (es) 2007-10-24
BRPI0619499A2 (pt) 2011-10-04
IL191930A0 (en) 2008-12-29
KR20150082688A (ko) 2015-07-15
IL191930A (en) 2013-11-28
EP3805367A1 (en) 2021-04-14
KR20240005984A (ko) 2024-01-12
JP2023171524A (ja) 2023-12-01
IL229348A0 (en) 2013-12-31
EP1957634A4 (en) 2010-01-27
RU2008122550A (ru) 2010-01-20
EP3072958A1 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
JP2023171524A (ja) 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2009518045A5 (OSRAM)
RU2364625C2 (ru) Генерирование дендритных клеток из моноцитарных предшественников дендритных клеток с помощью gm-csf в отсутствие дополнительных цитокинов
CA2509058A1 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
AU2023202977B2 (en) Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
AU2013206016B2 (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
HK40051623A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
AU2018260971B2 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
MX2008007289A (es) Composiciones y metodos para inducir la activacion de celulas dendriticas monociticas inmaduras
HK1193842A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
HK1128161A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
AU2013234394B2 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120628

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130805

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130913

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20131018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160614

R150 Certificate of patent or registration of utility model

Ref document number: 5954918

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250